Hafezi, Nikki L.
Aydemir, M. Enes
Lu, Nan-Ji
Torres-Netto, Emilio A.
Hillen, Mark
Koppen, Carina
Funding for this research was provided by:
Light for Sight Foundation, Zurich, Switzerland (01/2022)
Article History
Received: 10 August 2023
Accepted: 14 January 2024
First Online: 24 January 2024
Declarations
:
: Not applicable (in vitro experimental study).
: Not applicable.
: NH is CEO of EMAGine AG, a company producing a CXL device. MEA, NL, ET, MH and CK have no financial or proprietary interests in any product, method or material presented in this paper.